Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Robert Knox

Physician Assistant Defuniak Springs, FL Physician Assistant

NPI 1437167699 CMS profile 11154670

21 W Main Ave, Defuniak Springs, FL 32435

Open in the dashboard

General payments

$5,299

315 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Knox of Defuniak Springs, FL is reported in the CMS Open Payments database as having received $5,299 across 315 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $610 35
2024 General $1,091 59
2023 General $1,028 64
2022 General $1,025 66
2021 General $1,546 91

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Knox
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Robert Knox were reported at $610. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Robert Knox Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,546 $132 $37–$438 $132
2022 $1,025 $155 $48–$522 $149
2023 $1,028 $167 $52–$557 $160
2024 $1,091 $178 $55–$600 $164
2025 $610 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $975 71 payments
  2. GlaxoSmithKline, LLC. $679 36 payments
  3. AstraZeneca Pharmaceuticals LP $655 41 payments
  4. Novo Nordisk Inc $416 23 payments
  5. Pfizer Inc. $351 20 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $349 19 payments
  7. Dexcom, Inc. $239 10 payments
  8. Lilly USA, LLC $233 15 payments
  9. Amgen Inc. $152 9 payments
  10. Otsuka America Pharmaceutical, Inc. $135 6 payments
  11. Other $1,116 65 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,299 315 payments
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $632 32 payments
  2. VRAYLAR $496 39 payments
  3. Ozempic $416 23 payments
  4. RYBELSUS $394 22 payments
  5. Kerendia $349 19 payments
  6. AIRSUPRA $312 19 payments
  7. UBRELVY $305 19 payments
  8. FARXIGA $296 20 payments
  9. NURTEC ODT $257 14 payments
  10. Dexcom G6 Transmitter $205 8 payments
  11. Other $3,034 185 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 141 drugs

Part D claims

7,044

Median for Physician Assistant: 241

Drug cost

$399,809

Median for Physician Assistant: $4,110

Branded share of claims

19.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 61 $59,421
Eliquis Apixaban Brand 72 $50,706
Trulicity Dulaglutide Brand 46 $45,543
Vraylar Cariprazine Hcl Brand 22 $36,920
Ozempic Semaglutide Brand 29 $25,664
Xarelto Rivaroxaban Brand 31 $20,410
Januvia Sitagliptin Phosphate Brand 19 $15,146
Entresto Sacubitril/Valsartan Brand 22 $14,321
Mounjaro Tirzepatide Brand 12 $12,595
Ajovy Autoinjector Fremanezumab-Vfrm Brand 12 $9,798

The 10 drugs with the highest cost, of 141 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $157
$157 — —
UBRELVY
  • AbbVie, Inc. $115
$115 — —
VRAYLAR
  • AbbVie, Inc. $99
$99 22 —
MOUNJARO
  • Lilly USA, LLC $63
$63 12 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $59
$59 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

315 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record